Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response

专注于急性髓系白血病的领先临床阶段项目ICT01的收购，其中正在进行的I/II期EVICTION试验数据显示出高治疗反应。

ICT01 has the potential to be a new standard of care in combination in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults

ICT01有潜力成为一线治疗不适合急性髓系白血病的新标准，这是一种影响老年人的侵袭性血癌。

Ipsen to acquire all issued and outstanding shares of ImCheck Therapeutics, for which ImCheck Therapeutics’ shareholders will be eligible to receive a closing purchase price of 350 million euros and downstream payments contingent upon achievement of regulatory and sales-based milestones

益普生将收购ImCheck Therapeutics所有已发行和流通的股份，ImCheck Therapeutics的股东将有资格获得3.5亿欧元的交割购买价，以及取决于实现监管和销售相关里程碑的后续付款。

PARIS AND MARSEILLE, FRANCE, 22 October 2025

法国巴黎和马赛，2025年10月22日

– Ipsen (Euronext: IPN; ADR: IPSEY) and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies.

– 益普生（Euronext：IPN；ADR：IPSEY）和ImCheck Therapeutics今天宣布，双方已达成一项最终的股份购买协议，根据该协议，益普生将收购法国私营生物技术公司ImCheck Therapeutics的所有已发行和流通股份，该公司致力于开创下一代免疫肿瘤疗法。

The anticipated acquisition is focused on the lead Phase I/II program ICT01 in first line acute myeloid leukemia (AML).

预期的收购将专注于一线急性髓系白血病（AML）的领先一期/二期项目ICT01。

3

3

patients who are ineligible for intensive chemotherapy. ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer, and received Orphan Drug Designations from the U.S. Food and Drug Administration and European Medicines Agency in July 2025..

不符合强化化疗条件的患者。ICT01 是一种针对 BTN3A 的首创新单克隆抗体，BTN3A 是一种在癌症中广泛表达的关键免疫调节分子，并于 2025 年 7 月获得美国食品药品监督管理局和欧洲药品管理局的孤儿药资格认定。

Many AML patients are unable to tolerate intensive chemotherapy and must rely on lower-intensity options, which often deliver limited and short-lived benefit.

许多AML患者无法耐受高强度化疗，必须依赖低强度治疗方案，但这些方案通常效果有限且持续时间较短。

2

2

This high-risk, unfit population continues to face a significant unmet medical need, highlighting the urgency for new therapies that can improve survival and quality of life.

这一高风险、不适应人群仍然面临着显著未满足的医疗需求，突显了对能够提高生存率和生活质量的新疗法的迫切需求。

“At completion, the acquisition of ImCheck Therapeutics presents an opportunity for us to expand our pipeline in oncology and reinforces our commitment to deliver transformative therapies to the people who need them most,” said David Loew, CEO, Ipsen. “We feel confident that with the ICT01 promising data combined with Ipsen’s global development and commercialization expertise, we are well positioned to start a Phase IIb/III trial in 2026.” .

“收购ImCheck Therapeutics完成后，为我们扩展在肿瘤学领域的研发管线提供了机会，并再次彰显了我们致力于为最需要的患者提供变革性治疗的承诺，”益普生首席执行官David Loew表示。“我们相信，凭借ICT01的前景数据与益普生的全球开发和商业化专长相结合，我们有望在2026年启动IIb/III期试验。”

Interim data (n=45) orally presented at the annual American Society of Clinical Oncology 2025

中期数据（n=45）在2025年美国临床肿瘤学会年会上口头发表

1

1

from the Phase I/II EVICTION trial showed treatment with ICT01 in combination with venetoclax and azacitidine (Ven-Aza) achieved very encouraging high responses. In this single-arm trial, treatment response nearly doubled relative to those seen in historical standard of care data across all molecular subtypes in newly diagnosed patients including sub-types typically less responsive to standard of care (Ven-Aza)..

来自I/II期EVICTION试验的数据显示，ICT01与维奈托克和阿扎胞苷（Ven-Aza）联合治疗取得了非常令人鼓舞的高反应率。在这项单臂试验中，治疗反应率几乎比历史标准治疗数据翻了一番，涵盖了所有分子亚型的新诊断患者，包括通常对标准治疗（Ven-Aza）反应较差的亚型。

2

2

ICT01 in combination with Ven-Aza was also shown to be well tolerated, underscoring ICT01’s potential as a novel immunotherapy to improve outcomes for patients with AML.

ICT01与Ven-Aza联合使用也显示出良好的耐受性，突显了ICT01作为改善AML患者预后的新型免疫疗法的潜力。

“We are thrilled to become part of Ipsen, a company whose ambition for transformative care matches our commitment to bringing innovative treatments to patients. This transaction recognizes groundbreaking science originating from French academia,” said Pierre d’Epenoux, CEO, ImCheck Therapeutics. “It also highlights the exceptional work the ImCheck team and our partners have achieved to advance the understanding of butyrophilns and gamma delta T cells.

“我们非常高兴能够成为Ipsen的一部分，这家公司的变革性护理雄心与我们为患者带来创新治疗的承诺不谋而合。此次交易认可了源自法国学术界的开创性科学成果，”ImCheck Therapeutics首席执行官皮埃尔·德潘努（Pierre d’Epenoux）表示。“这也突显了ImCheck团队和我们的合作伙伴在推进对乳酸球蛋白和伽马德尔塔T细胞的理解方面所取得的卓越成就。”

Joining Ipsen will help us accelerate ICT01 toward registrational studies and commercialization. I remain grateful to the patients and investors for their contributions to furthering ImCheck’s pioneering science.”.

加入益普生将有助于我们加速推进ICT01的注册研究和商业化进程。我对患者和投资者为推动ImCheck的开创性科学所做出的贡献深表感谢。

Transaction details

交易详情

Under the terms of the agreement, through a wholly owned affiliate of Ipsen SAS, shareholders of ImCheck Therapeutics will receive a 350 million euros payment on a cash-free and debt-free basis at closing of the transaction, and deferred payments contingent upon the achievement of specified regulatory approvals and sales-based milestones, for a total potential consideration up to 1 billion euros..

根据协议条款，通过益普生 SAS 的全资子公司，ImCheck Therapeutics 的股东将在交易完成时获得 3.5 亿欧元的无现金、无债务支付，并在达成特定监管批准和基于销售的里程碑后获得延期付款，潜在总对价高达 10 亿欧元。

The transaction is expected to close by the end of Q1 2026, subject to fulfilment of customary closing conditions including the expiration or termination of any required regulatory and governmental approvals under French and U.S. regulations.

该交易预计将在2026年第一季度末前完成，但需满足惯例的交割条件，包括根据法国和美国法规获得任何所需的监管和政府批准的到期或终止。

Advisors

顾问

Allen & Overy Shearman (Paris) is acting as legal counsel to Ipsen. Centerview Partners is acting as exclusive financial advisor to ImCheck Therapeutics with Goodwin (London) and Dentons (Paris) acting as legal counsel.

安理国际律师事务所（巴黎）担任益普生的法律顾问。Centerview Partners 担任 ImCheck Therapeutics 的独家财务顾问，Goodwin（伦敦）和 Dentons（巴黎）担任其法律顾问。

About the EVICTION trial

关于EVICTION试验

EVICTION is a first-in-human, dose-escalation (Part 1) and cohort-expansion (Part 2) clinical trial of ICT01 in patients with various advanced relapsed or refractory solid or hematologic cancers that have exhausted standard-of-care treatment options, as well as newly-diagnosed AML. More information on the EVICTION trial can be found at clinicaltrials.gov (NCT04243499)..

EVICTION是一项针对ICT01的首次人体临床试验，包含剂量递增（第1部分）和队列扩展（第2部分），适用于多种晚期复发或难治性实体瘤或血液癌症患者，这些患者已穷尽标准治疗方案，同时也包括新诊断的急性髓系白血病（AML）。有关EVICTION试验的更多信息可访问clinicaltrials.gov（NCT04243499）。

About ICT01

关于ICT01

ICT01 is a humanized, anti-BTN3A (also known as CD277) monoclonal antibody that promotes the recognition and elimination of tumor cells by γ9δ2 T cells, which are responsible for immunosurveillance of malignancy and infections. The three isoforms of BTN3A targeted by ICT01 are overexpressed on many solid tumors (e.g., melanoma, urothelial cell, colorectal, ovarian, pancreatic, and lung cancer) and hematologic malignancies (e.g., leukemia and lymphomas) and are also expressed on the surface of innate (e.g., γδ T cells and NK cells) and adaptive immune cells (T cells and B cells).

ICT01是一种人源化的抗BTN3A（也称为CD277）单克隆抗体，能够促进γ9δ2 T细胞对肿瘤细胞的识别和清除。γ9δ2 T细胞负责对恶性肿瘤和感染进行免疫监视。ICT01靶向的三种BTN3A异构体在许多实体瘤（如黑色素瘤、尿路上皮细胞癌、结直肠癌、卵巢癌、胰腺癌和肺癌）和血液系统恶性肿瘤（如白血病和淋巴瘤）中过表达，并且还表达在先天性免疫细胞（如γδ T细胞和NK细胞）以及适应性免疫细胞（T细胞和B细胞）的表面。

Binding to BTN3A is essential for the activation of the anti-tumor immune response of γ9δ2 T cells. By altering the conformation of BTN3A, ICT01 promotes this binding, thereby selectively activating circulating γ9δ2 T cells. This leads to migration of γ9δ2 T cells out of the circulation and into the tumor tissue, and triggers a downstream immunological cascade through secretion of pro-inflammatory cytokines, including but not limited to IFNγ and TNFα, further augmenting the anti-tumor immune response.

与BTN3A的结合对于γ9δ2 T细胞的抗肿瘤免疫反应激活至关重要。通过改变BTN3A的构象，ICT01促进这种结合，从而选择性激活循环中的γ9δ2 T细胞。这导致γ9δ2 T细胞从循环系统迁移到肿瘤组织，并通过分泌促炎性细胞因子（包括但不限于IFNγ和TNFα）触发下游免疫级联反应，进一步增强抗肿瘤免疫反应。

Anti-tumor activity and efficacy of ICT01 have been shown in patients across several cancer indications..

ICT01在多个癌症适应症的患者中显示出抗肿瘤活性和疗效。

About Ipsen

关于益普生

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

我们是一家全球生物制药公司，专注于在三个治疗领域为患者带来变革性药物：肿瘤学、罕见病和神经科学。

Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries..

我们的产品线由内外部创新提供动力，并得到近百年开发经验以及美国、法国和英国的全球中心的支持。我们在 40 多个国家/地区的团队以及世界各地的合作伙伴关系使我们能够将药物带给 100 多个国家/地区的患者。

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

益普生在巴黎（泛欧交易所：IPN）和美国通过一级赞助美国存托凭证计划（ADR：IPSEY）上市。欲了解更多信息，请访问ipsen.com。

About ImCheck Therapeutics

关于ImCheck Therapeutics

ImCheck Therapeutics is developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. By unlocking the power of γ9δ2 T cells, ImCheck’s innovative approach has the potential to transform treatments across oncology, autoimmune, and infectious diseases. .

ImCheck Therapeutics 正在开发一种针对乳脂球蛋白的新一代免疫治疗抗体，乳脂球蛋白是一种新型的免疫调节剂超家族。通过释放 γ9δ2 T 细胞的力量，ImCheck 的创新方法有潜力变革肿瘤学、自身免疫和传染病的治疗方法。

The lead clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rationale combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs.

领先的临床阶段项目ICT01已进入后期试验，展示了一种调节先天免疫和适应性免疫的独特作用机制。这些“首创”激活抗体相较于第一代免疫疗法，尤其在与免疫检查点抑制剂和免疫调节抗癌药物的合理组合中，可能带来更优越的临床效果。

Additionally, ImCheck’s pipeline compounds are progressing toward clinical development for autoimmune and infectious diseases. .

此外，ImCheck的管道化合物正朝着自身免疫和传染病的临床开发方向发展。

The company benefits from the pioneering research of Prof. Daniel Olive (Institut Paoli Calmettes, INSERM, CNRS, Aix-Marseille University), a global leader in γ9δ2 T cells and butyrophilins, as well as the expertise of a seasoned management team and the commitment of leading French, European and U.S.

公司受益于丹尼尔·奥利弗教授（Daniel Olive，Institut Paoli Calmettes，INSERM，CNRS，艾克斯-马赛大学）在γ9δ2 T细胞和乳铁蛋白领域的开创性研究，以及经验丰富的管理团队的专业知识和法国、欧洲及美国主要机构的全力支持。

investors including Kurma Partners, Eurazeo, Bpifrance through its Innobio 2 and Large Venture funds, Andera Partners, Pfizer Ventures, Gimv, EQT Life Sciences, Earlybird, Wellington Partners, Pureos Bioventures, Invus, Agent Capital, Boehringer Ingelheim Venture Fund, Alexandria Venture Investments, and Blood Cancer United (previously LLS)®..

包括Kurma Partners、Eurazeo、Bpifrance通过其Innobio 2和Large Venture基金、Andera Partners、Pfizer Ventures、Gimv、EQT Life Sciences、Earlybird、Wellington Partners、Pureos Bioventures、Invus、Boehringer Ingelheim Venture Fund、Alexandria Venture Investments以及Blood Cancer United（之前为LLS）®在内的投资者。

For further information:

更多信息请参见：

https://www.imchecktherapeutics.com/

https://www.imchecktherapeutics.com/

Ipsen Contacts

联系人

Investors

投资者

Henry Wheeler

亨利·惠勒

henry.wheeler@ipsen.com

henry.wheeler@ipsen.com

+33 7766471149

+33 7766471149

Khalid Deojee

哈立德·德奥杰

khalid.deojee@ipsen.com

khalid.deojee@ipsen.com

+33 666019526

+33 666019526

Media

媒体

Sally Bain

萨莉·贝恩

sally.bain@ipsen.com

sally.bain@ipsen.com

+1 8573200517

+1 8573200517

Anne Liontas

安妮·利昂塔斯

anne.liontas.ext@ipsen.com

anne.liontas.ext@ipsen.com

+33 0767347296

+33 0767347296

ImCheck Contacts

ImCheck 联系人

Media

媒体

Gretchen Schweitzer (EU and US)

格雷琴·施魏策尔（欧盟和美国）

ImCheck@trophic.eu

ImCheck@trophic.eu

+49 1728618540

+49 1728618540

Céline Voisin (France)

塞琳·沃森（法国）

Imcheck@atcg-partners.com

Imcheck@atcg-partners.com

+33 (0)6 62 12 53 39

+33 (0)6 62 12 53 39

References

参考文献

Dumas et al. γ9δ2 T-cell activation with ICT01 combined with azacitidine-venetoclax for older/unfit adults with newly diagnosed AML: preliminary efficacy and dose selection in Phase 1/2 study EVICTION. ASCO 2025. Available here:

Dumas 等人。在γ9δ2 T细胞激活中使用ICT01联合阿扎胞苷-维奈托克治疗新诊断的不适合强化疗的老年AML患者：1/2期研究EVICTION的初步疗效与剂量选择。ASCO 2025。可在此处获取：

https://www.ImChecktherapeutics.com/fileadmin/Posters_Prez/ASCO2025-ICT01-AzaVen.pdf

https://www.ImChecktherapeutics.com/fileadmin/Posters_Prez/ASCO2025-ICT01-AzaVen.pdf

Kone AS, Ait Ssi S, Sahraoui S, Badou A. BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment.

Kone AS, Ait Ssi S, Sahraoui S, Badou A。BTN3A：一个有前景的癌症预后和治疗的免疫检查点。

Int J Mol Sci

国际分子科学杂志

. 2022;23(21):13424. Published 2022 Nov 3. doi:10.3390/ijms232113424

. 2022;23(21):13424. 发表于2022年11月3日. doi:10.3390/ijms232113424

Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia.

Short NJ, Rytting ME, Cortes JE。急性髓系白血病。

Lancet

柳叶刀

. 2018;392(10147):593-606. doi:10.1016/S0140-6736(18)31041-9

. 2018;392(10147):593-606. doi:10.1016/S0140-6736(18)31041-9

Disclaimers and/or forward-looking statements

免责声明和/或前瞻性陈述

The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein.

本文件中包含的前瞻性声明、目标和指标均基于益普生的管理策略、当前观点和假设。这些声明涉及已知和未知的风险与不确定性，可能导致实际结果、业绩或事件与此处预期的情况有重大差异。

All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations.

上述所有风险均可能影响益普生未来实现其财务目标的能力，这些目标是在假设宏观经济状况合理的情况下根据当前可获得的信息制定的。使用“相信”、“预期”和“预计”等词语及类似表述旨在识别前瞻性陈述，包括益普生对未来事件的预期，包括监管文件提交和决定。

Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data.

此外，本文件中描述的目标是在未考虑外部增长假设和潜在未来收购的情况下制定的，这些假设和收购可能会改变这些参数。这些目标基于益普生认为合理的数据和假设。这些目标取决于未来可能发生的条件或事实，而不仅仅依赖于历史数据。

Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons.

鉴于某些风险和不确定性的发生，实际结果可能与这些目标有显著差异，尤其是处于早期开发阶段或临床试验中的有前景的药物，可能最终永远不会上市或达到其商业目标，特别是由于监管或竞争原因。

Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards t.

益普生可能面临或可能会面临来自仿制药的竞争，这可能会导致市场份额的损失。此外，研发过程涉及多个阶段，每个阶段都存在益普生可能无法实现其目标并被迫放弃相关努力的重大风险。

Attachment

附件

Ipsen PR_Ipsen to acquire ImCheck Therapeutics_22102025

益普生公关_益普生将收购ImCheck Therapeutics_2025年10月22日